Spironolactone in Hidradenitis Suppurativa: A Single-Center Study

March 2024 in “ International Journal of Women’s Dermatology ”

Rahul Masson, Sarah Park, Terri Shih, Marcia Hogeling, Vivian Y. Shi, Jennifer L. Hsiao

spironolactone hidradenitis suppurativa polycystic ovarian syndrome menstrual HS flares

Studysummary This study observed that spironolactone improved hidradenitis suppurativa in over 80% of female patients at 3 and 6 months, with no significant differences in response due to menstrual flares or polycystic ovarian syndrome, but mild adverse events were reported.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on journals.lww.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Spironolactone Therapy for Hidradenitis Suppurativa

19 citations , October 2019 in “Clinical and Experimental Dermatology”

This study found that spironolactone significantly reduced pain, lesion count, and disease severity in patients with hidradenitis suppurativa, as reported in multiple patient cohorts.

research Antiandrogen Therapy with Spironolactone for the Treatment of Hidradenitis Suppurativa

48 citations , July 2018 in “Journal of The American Academy of Dermatology”

This study observed that treatment with spironolactone significantly improved pain, inflammatory lesion count, and HS-PGA scores among female patients with hidradenitis suppurativa, suggesting its potential as an effective treatment option, even at lower doses, despite no change in Hurley stage or fistula count.

research Endocrinologic Aspects of Hidradenitis Suppurativa

45 citations , November 2015 in “Dermatologic Clinics”

This review discusses the potential hormonal and metabolic factors influencing hidradenitis suppurativa and highlights the need for further research to explore hormonal dysregulation's role in the disease.